Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$141.47 USD

141.47
580,774

-0.87 (-0.61%)

Updated Jun 10, 2024 04:00 PM ET

After-Market: $141.50 +0.03 (0.02%) 4:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 248)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merit Medical (MMSI) Q2 Earnings Beat, FY22 View Revised

by Zacks Equity Research

Merit Medical (MMSI), in the second quarter, benefits from revenue growth in both its segments and from all product categories within its Cardiovascular unit.

Urmimala Biswas headshot

3 MedTech Stocks That are Likely to Beat This Earnings Season

by Urmimala Biswas

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how STE, TMO and IDXX are poised ahead of their earnings releases.

    Tenet Healthcare (THC) Q2 Earnings Beat, Trims '22 EPS View

    by Zacks Equity Research

    Tenet Healthcare's (THC) second-quarter earnings benefit from strong Ambulatory Care and Conifer segments. However, a trimmed EPS view for 2022 might raise concerns for investors.

    Quest Diagnostics (DGX) Tops Q2 Earnings Estimates, Ups View

    by Zacks Equity Research

    Banking on consistent improvement in the company's Base business, Quest Diagnostics (DGX) raises its full-year 2022 guidance.

    Quest Diagnostics (DGX) Tops Q2 Earnings and Revenue Estimates

    by Zacks Equity Research

    Quest Diagnostics (DGX) delivered earnings and revenue surprises of 4.42% and 4.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    Nalak Das headshot

    5 Dividend-Paying Stocks to Buy Ahead of Earnings Next Week

    by Nalak Das

    Five dividend-paying companies will report second-quarter 2022 earnings results next week. These are: HAL, FNB, DGX, SLB and NEP.

    Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

    by Zacks Equity Research

    Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Quest Diagnostics (DGX) to Report Q2 Earnings: What's In Store?

    by Zacks Equity Research

    Quest Diagnostics (DGX) second-quarter 2022 results will likely have gained from an ongoing rebound in the base business.

    Quest Diagnostics (DGX), CDC Sign New COVID-19 Testing Deal

    by Zacks Equity Research

    Quest Diagnostics (DGX) and the CDC tie up to provide COVID testing for underserved communities free of cost across the United States.

    Quest Diagnostics' (DGX) Base Business Grows Despite Margin Woes

    by Zacks Equity Research

    Quest Diagnostics (DGX) continues to make inroads with its health plans, gaining share and increasing revenues faster than the market.

    Walgreens Boots (WBA) Q3 Earnings Top Estimates, Revenues Miss

    by Zacks Equity Research

    Walgreens Boots (WBA) reports better-than-expected Q3 earnings, with robust sales contributions from the International and Walgreens Health segments.

    Option Care (OPCH) Stock Jumps 5.6%: Will It Continue to Soar?

    by Zacks Equity Research

    Option Care (OPCH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

    Is Quest Diagnostics (DGX) a Great Value Stock Right Now?

    by Zacks Equity Research

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

    Here's Why You Should Hold Quest Diagnostics (DGX) Stock Now

    by Zacks Equity Research

    Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in its base business and encouraging 2022 guidance.

    Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now

    by Zacks Equity Research

    Investors are optimistic about Quest Diagnostics (DGX) on a strong recovery in the base business and the raised 2022 outlook.

    Quest Diagnostics (DGX) Just Reclaimed the 200-Day Moving Average

    by Zacks Equity Research

    Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?

    Encompass Health (EHC) Down 6.4% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now

    by Zacks Equity Research

    Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in base business and raised 2022 outlook.

    Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down

    by Zacks Equity Research

    Based on a bullish expectation for the remainder of 2022, Quest Diagnostics (DGX) raises its full-year guidance.

    Quest Diagnostics (DGX) Beats Q1 Earnings Estimates

    by Zacks Equity Research

    Quest Diagnostics (DGX) delivered earnings and revenue surprises of 10.65% and 1.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Should You Buy Quest Diagnostics (DGX) Ahead of Earnings?

    by Zacks Equity Research

    Quest Diagnostics (DGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Quest Diagnostics (DGX) Q1 Earnings to Grow on Base Business

    by Zacks Equity Research

    Quest Diagnostics (DGX) is expected to report a strong first half of Q1 with a growing number of cases and then a dull second half on gradual stabilization in testing demand.

    Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    by Zacks Equity Research

    Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Quest Diagnostics (DGX) Inks New Diabetic Retinal Imaging Deal

    by Zacks Equity Research

    Quest Diagnostics' (DGX) new collaboration with IRIS will enhance access to diabetic retinopathy screening in the United States.

    Quest Diagnostics' (DGX) Volumes Aid, Price Pressure Stays

    by Zacks Equity Research

    According to Quest Diagnostics (DGX), the delay of the 2022 PAMA cuts announced last year proved beneficial for the industry and Medicare beneficiaries.